Clinical Trial Manager
I originally trained as a Biochemist, and have been working in healthcare research since 1999. Initially I worked as a research assistant in the Diabetes Trials Unit in Oxford. After completing a DPhil in Immunology, investigating the Varicella Zoster Virus. I moved back into clinical trials.
I joined the Department on 2010 as a Clinical Trial Co-ordinator, initially working on the MAC trial, investigating the use of Montelukast in post-infectious cough in adults, and the CAPS study, looking at the epidemiology of persistent cough in children.
Subsequently, I joined the Health Behaviours & other conditions theme, as trial manager for the EDGE study, investigating self-monitoring in people with COPD. Alongside this I ran a the Oxford arm of the MASTERMIND study, investigating how people responded to different diabetes medication and their medication adherence.
I have also been involved in various stages of a number of other trials including, POC HbA1c, CANDID, TasminH4, StAR-2D and Summit-D.
I am currently a member of the Cardiovascular and Renal Theme. I am working with Professor Richard Hobbs managing the BARACK-D Trial, which investigates the use of Spironolactone in patients with Chronic Kidney Disease.
I am also working with Professor Rafael Perera, as trial manager for the FORM2C study, investigating the optimal frequency of testing, and the use of different test to monitor kidney function.
I am a member of the UK Trial Managers Network and for since2015 I have taught clinical trial management for the University of Oxford and a lecturer and facilitator on the Clinical Trials Management module.
Farmer A. et al, (2021)
Farmer A. et al, (2021), JMIR Research Protocols
Perera R. et al, (2021), Programme Grants for Applied Research, 9, 1 - 218
FORM-2C (Frequency of Renal Monitoring – Creatinine and Cystatin C): an observational cohort study of primary care patients with reduced eGFR
Fleming S. et al, (2021), British Journal of General Practice
On-site monitoring of primary outcomes is important in primary care clinical trials: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK-D) Trial a case study
Jones L. et al, (2019), TRIALS, 20